Var vel også en helligdag (19.jan) i USA den uken, vet ikke om tallene tar høyde for det?
Lilly CEO ute med noen kommentarer (som kan tyde på mindre enn ventet kannibalisering?)
"Ricks said he noticed that nearly all of the early adopters of Novo’s Wegovy pill are new to GLP-1 treatments rather than users of existing injections, so “it’s expansive, it’s reaching more patients and that’s great.” "
Og data fra REIMAGINE 2 ute:
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
2026-02-02 16:43:01
- CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1.
- CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.
- Superiority was established on both weight loss and HbA1c versus the individual components.
- In the trial, CagriSema appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies.
Bagsværd, Denmark, 2 February 2026 – Novo Nordisk today announced headline results from REIMAGINE 2, a phase 3 trial from the global REIMAGINE clinical trial programme. CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.
REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of the amylin receptor agonist, cagrilintide, and the GLP-1 receptor agonist, semaglutide) in two different doses (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) compared to two different doses of semaglutide (2.4 mg and 1.0 mg), cagrilintide (2.4 mg), and placebo. The trial included 2,728 people with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor. Approximately 40% of all people were using an SGLT2 inhibitor before initiating the trial.
When evaluating the effects of treatment, if all people adhered to treatment1, and from a mean HbA1c baseline of 8.2%, people treated with CagriSema 2.4 mg/2.4 mg achieved superior HbA1c reduction of 1.91%-points after 68 weeks compared to 1.76%-points with semaglutide 2.4 mg. From a mean baseline body weight of 101 kg, people treated with CagriSema 2.4 mg/2.4 mg achieved superior weight loss of 14.2% after 68 weeks compared to 10.2% with semaglutide 2.4 mg. No weight loss plateau was observed at week 68 for CagriSema. With CagriSema 2.4 mg/2.4 mg, 43% of the people achieved ≥15% weight loss and 24% achieved ≥20% weight loss.
Efficacy estimand results
| From week 0 to 68 |
HbA 1c reduction
|
Weight loss |
| CagriSema 2.4 mg/2.4 mg |
-1.91%-pointsa |
-14.2%a |
| Semaglutide 2.4 mg |
-1.76%-points |
-10.2% |
| Placebo |
+0.09%-points |
-1.5% |
a Statistically significant compared to semaglutide (2.4 mg), estimated mean.
When applying the treatment-regimen estimand2, people treated with CagriSema 2.4 mg/2.4 mg achieved superior HbA1c reduction of 1.80%-points after 68 weeks compared to 1.68%-points with semaglutide 2.4 mg. In addition, people treated with CagriSema 2.4 mg/2.4 mg achieved superior weight loss of 12.9% after 68 weeks compared to 9.2% with semaglutide 2.4 mg.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with incretin and amylin-based therapies.
“We are very pleased by the clinical profile of CagriSema in type 2 diabetes patients, including a confirmation of the very strong weight loss data seen with CagriSema in the obesity trials”, said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “By combining semaglutide and cagrilintide, we’re seeing superior outcomes in both blood glucose control and weight reduction beyond those achieved with each therapy individually. The results strengthen our belief that CagriSema could be the first amylin-based combination therapy and a promising treatment option for individuals with type 2 diabetes, who also has a focus on weight loss.”
Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk will approach authorities to discuss the regulatory pathway for CagriSema in type 2 diabetes.
The detailed results from REIMAGINE 2 will be presented at a scientific conference in 2026. CagriSema for weight management was submitted to the US FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials.
